Anne Li 1/1/17
The National Institute for Health and Care Excellence (NICE) has published draft guidance stating that the breast cancer drug trastuzumab emtansine (also known as Kadcyla) will not be made routinely available through the NHS. NICE had previously assessed the drug, manufactured by Roche, as being too expensive for the NHS to fund, with the latest guidance issued in 2015. The new draft guidance continues that stance, though the drug will still be available in England through the Cancer Drugs Fund while NICE consults with a final decision expected in February. At its full price the drug costs around £90,000 per patient. But NICE was looking at a scheme where the NHS would pay the full price for a patient for just over a year, with a discount on subsequent treatment.
See original article at: